Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients with Coronary Artery Narrowing after Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent

JACC: Cardiovascular Interventions

Volumn 8, Issue 8, 2015, Pages 1053-1063

  Ishibashi, Yuki ^a   Muramatsu, Takashi ^a,b   Nakatani, Shimpei ^a   Sotomi, Yohei ^c   Suwannasom, Pannipa ^a   Grundeken, Maik J ^c   Cho, Yun Kyeong ^a   Garcia Garcia, Hector M ^a   Van Boven, Ad J ^d   Piek, Jan J ^c   Sabaté, Manel ^e   Helqvist, Steffen ^f   Baumbach, Andreas ^g   McClean, Dougal ^h   De Sousa Almeida, Manuel ⁱ   Wasungu, Luc ^j   Miquel Hebert, Karine ^j   Dudek, Dariusz ^k   Chevalier, Bernard ^l   Onuma, Yoshinobu ^a   Serruys, Patrick W ^m   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g Bristol Heart Institute   (United Kingdom)

^h CHRISTCHURCH HOSPITAL   (New Zealand)

ⁱ HOSPITAL DE SANTA CRUZ   (Portugal)

^j ABBOTT VASCULAR   (United States)

^k JAGIELLONIAN UNIVERSITY   (Poland)

^l Institut Jacques Cartier   (France)

^m NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

bioresorbable scaffold; cardiac biomarker; device overlap; periprocedural myocardial infarction

Indexed keywords

CREATINE KINASE; EVEROLIMUS; TROPONIN; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CREATINE KINASE MB; METAL;

ADULT; ANGIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CREATINE KINASE BLOOD LEVEL; EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DEVICES; DRUG ELUTING STENT; EUROPE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NEW ZEALAND; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROSTHESIS DESIGN; RISK FACTOR; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ABSORBABLE IMPLANTS; AGED; BIOMARKERS; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DRUG-ELUTING STENTS; EUROPE; EVEROLIMUS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NEW ZEALAND; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; TROPONIN; UP-REGULATION;

EID: 84937715345     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.06.001     Document Type: Article

References (30)

1. P.W. Serruys, J.A. Ormiston, Y. Onuma, and et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
2. J.A. Ormiston, P.W. Serruys, E. Regar, and et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 2008 899 907
3. J.A. Ormiston, M.W. Webster, and G. Armstrong First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent Catheter Cardiovasc Interv 69 2007 128 131
4. Y. Onuma, P.W. Serruys, J.A. Ormiston, and et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial EuroIntervention 6 2010 447 453
5. P.W. Serruys, Y. Onuma, D. Dudek, and et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes J Am Coll Cardiol 58 2011 1578 1588
6. P.W. Serruys, Y. Onuma, J.A. Ormiston, and et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes Circulation 122 2010 2301 2312
7. P.W. Serruys, Y. Onuma, H.M. Garcia-Garcia, and et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months EuroIntervention 9 2014 1271 1284
8. R. Diletti, P.W. Serruys, V. Farooq, and et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design Am Heart J 164 2012 654 663
9. T. Muramatsu, Y. Onuma, H.M. Garcia-Garcia for the ABSORB-EXTEND Investigators Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials J Am Coll Cardiol Intv 6 2013 247 257
10. S. Garg, and P.W. Serruys Coronary stents: current status J Am Coll Cardiol 56 Suppl 10 2010 S1 S42
11. Y. Onuma, J. Ormiston, and P.W. Serruys Bioresorbable scaffold technologies Circ J 75 2011 509 520
12. G.S. Roubin, A.D. Cannon, S.K. Agrawal, and et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty Circulation 85 1992 916 927
13. M.R. Bell, G.S. Reeder, K.N. Garratt, P.B. Berger, K.R. Bailey, and D.R. Holmes Jr. Predictors of major ischemic complications after coronary dissection following angioplasty Am J Cardiol 71 1993 1402 1407
14. P. Vranckx, V. Farooq, S. Garg, and et al. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting Heart 98 2012 1424 1430
15. K. Thygesen, J.S. Alpert, A.S. Jaffe for the Joint ESC/ACCF/AHA/WHF Task Force Members Chairpersons Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
16. M.H. Pervaiz, P. Sood, K. Sudhir, and et al. Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions Circ Cardiovasc Interv 5 2012 150 156
17. P.W. Serruys, B. Chevalier, D. Dudek, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
18. D.W. Park, Y.H. Kim, S.C. Yun, and et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention Eur Heart J 34 2013 1662 1669
19. P.K. Myint, C.S. Kwok, M.O. Bachmann, S. Stirling, L. Shepstone, and M.J. Zaman Prognostic value of troponins in acute coronary syndrome depends upon patient age Heart 100 2014 1583 1590
20. A.J. Lansky, and G.W. Stone Periprocedural myocardial infarction: prevalence, prognosis, and prevention Circ Cardiovasc Interv 3 2010 602 610
21. R. Mehran, G. Dangas, G.S. Mintz, and et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients Circulation 101 2000 604 610
22. A. Maehara, G.S. Mintz, and N.J. Weissman Advances in intravascular imaging Circ Cardiovasc Interv 2 2009 482 490
23. T. Kawamoto, H. Okura, Y. Koyama, and et al. The relationship between coronary plaque characteristics and small embolic particles during coronary stent implantation J Am Coll Cardiol 50 2007 1635 1640
24. R. Merla, N.K. Reddy, F.W. Wang, B.F. Uretsky, A. Barbagelata, and Y. Birnbaum Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis Am J Cardiol 100 2007 770 776
25. V. Farooq, P.W. Serruys, P. Vranckx, and et al. Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation: a substudy from the Synergy between Percutaneous Coronary Interventions with Taxus and Cardiac Surgery (SYNTAX) trial Int J Cardiol 168 2013 5287 5292
26. J. Herrmann Peri-procedural myocardial injury: 2005 update Eur Heart J 26 2005 2493 2519
27. D.W. Park, Y.H. Kim, S.C. Yun, and et al. Impact of the angiographic mechanisms underlying periprocedural myocardial infarction after drug-eluting stent implantation Am J Cardiol 113 2014 1105 1110
28. V. Farooq, P.W. Serruys, J.H. Heo, and et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice J Am Coll Cardiol Intv 6 2013 523 532
29. G. Nakazawa, M. Nakano, F. Otsuka, and et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis Circ Cardiovasc Interv 4 2011 38 46
30. T. Palmerini, G. Biondi-Zoccai, D. Della Riva, and et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol 62 2013 1915 1921